Leerink Partners Starts AnaptysBio (ANAB) at Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/10/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mailGet Alerts ANAB Hot Sheet
Price: $45.95 -0.56%
Rating Summary:
13 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
13 Buy, 7 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
Leerink Partners analyst David Risinger initiates coverage on AnaptysBio (NASDAQ: ANAB) with a Outperform rating and a price target of $47.00.
For an analyst ratings summary and ratings history on AnaptysBio click here. For more ratings news on AnaptysBio click here.
Shares of AnaptysBio closed at $21.27 yesterday.
You May Also Be Interested In
- UBS Assumes PennantPark Floating Rate Capital (PFLT) at Buy
- Chardan Starts Duos Technologies Group (DUOT) at Neutral
- BofA Securities Starts Penguin Solutions (PENG) at Buy
Create E-mail Alert Related Categories
New CoverageSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
